SAM
FOLD

Stansberry Asset Management’s Amicus Therapeutics FOLD Stock Holding History

Stansberry Asset Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-62,009
Closed -$969K – 89
2018
Q2 		$969K Sell
62,009
-1,189
-2% -$18K 0.32% 58
2018
Q1 		$950K Buy
+63,198
New +$962K 0.47% 48

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Stansberry Asset Management's FOLD Position: Q3 2018 in Review

Stansberry Asset Management sold out of Amicus Therapeutics (FOLD) in Q3 2018, closing a stake of 62,009 shares — an estimated $969K sold.

Stansberry Asset Management first reported a position in FOLD in Q1 2018 and held it in 2 quarters. The position peaked at $969K in Q2 2018. 204 funds tracked by Wall St. Rank hold FOLD as of Q3 2018.

  • Stansberry Asset Management reported no remaining Amicus Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Stansberry Asset Management sold 62,009 Amicus Therapeutics shares in Q3 2018, an estimated $969K.
  • Stansberry Asset Management first reported a position in Amicus Therapeutics in Q1 2018 and held it in 2 quarters.
  • Stansberry Asset Management's Amicus Therapeutics position peaked at $969K in Q2 2018.
  • 204 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2018.

Based on Stansberry Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.